Mace Announces 2021 Investor Conference Schedule newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
Bemarituzumab is a Strong Strategic Fit With Amgen’s Innovative Oncology Portfolio
Amgen to Host Investor Call at 10:30 a.m. EST
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 4, 2021 – Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. This acquisition adds Five Prime’s innovative pipeline to Amgen’s leading oncology portfolio.
Five Prime’s lead asset, bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer. Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients
Share this article
Share this article
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 4, 2021 /PRNewswire/ Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. This acquisition adds Five Prime s innovative pipeline to Amgen s leading oncology portfolio.
(PRNewsfoto/Amgen)
Five Prime s lead asset, bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer. Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer, as well as other solid t
/PRNewswire/ Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the 2021 American Academy of Allergy, Asthma &.
Amgen To Present At Guggenheim Healthcare Talks Oncology Day
Amgen today announced that Greg Friberg vice president and global oncology therapeutic area head at Amgen, will participate in a fireside chat as part of the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, Feb. 12 at 12:30 p.m. ET . Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The …
– Amgen (NASDAQ:AMGN) today announced that Greg Friberg vice president and global oncology therapeutic area head at Amgen, will participate in a fireside chat as part of the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, Feb. 12 at 12:30 p.m. ET .